



THE UNIVERSITY OF CHICAGO

ANNUAL UPDATES FROM ASH 2021

PHYSICIAN CREDIT: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT: University of Chicago Medicine is approved as a provider of nursing continuing professional development by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. (OBN-001-91). This live activity is designated for a maximum of 5.25 continuing nursing education units.

AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AMERICAN BOARD OF PEDIATRICS MOC PART II CREDIT: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

OTHER HEALTH PROFESSIONAL CREDIT: Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

EDUCATIONAL GRANTS/COMMERCIAL SUPPORT: A complete listing of commercial support received will be provided in the conference materials.

DISCLOSURE DECLARATIONS: As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.



AT THE FOREFRONT

UChicago Medicine

The University of Chicago
Center for Continuing
Medical Education
5841 S. Maryland Ave., MC 1137
Chicago, IL 60637

Follow us on Twitter: @UChicagoCME




FOR MORE INFORMATION AND TO REGISTER:

Scan the QR code or visit www.ChicagoPostASH.com

QUESTIONS? Contact Meeting Achievements at

Janelle@meetingachievements.com Or 219.465.1115



THE UNIVERSITY OF CHICAGO

ANNUAL UPDATES FROM ASH 2021

PRACTICE CHANGING ABSTRACTS

FRIDAY, FEBRUARY 18, 2022

HYBRID FORMAT: VIRTUAL + LIMITED IN-PERSON ATTENDANCE



AT THE FOREFRONT

UChicago Medicine

COURSE DIRECTOR

Michael Bishop, MD | Professor of Medicine

Director of the Jonas Center for Cellular Therapy

University of Chicago Medicine

www.ChicagoPostASH.com

CONTINUING EDUCATION ACCREDITATION BY UNIVERSITY OF CHICAGO

PROGRAM INFORMATION

COURSE DESCRIPTION

Our goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, the 7th Annual Updates from ASH 2021: Practice Changing Abstracts will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art management of newly-diagnosed and relapsed blood cancers. Our overarching goal is to keep all healthcare professionals who care for patients with hematologic malignancies to stay abreast of the latest scientific updates, innovative ideas, and timeliest issues related to their care. This conference will provide the target audience with information that can help improve patient management and care strategies. Participants will discuss with content experts rapidly evolving developments, discover new treatments for patients, and improve overall practice paradigms. We will educate and empower community-based oncologists on best practices for treating hematologic cancers and inform them of the indicators for when to refer a patient for expert quaternary level care for advanced cellular therapies.

In addition to virtual participation, we are excited to welcome participants back to the conference in person. Like the 63rd ASH Annual Meeting, clinicians will be able to learn from each other while in the same room.

TARGET AUDIENCE

This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, resident and fellow trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to the treatment of hematologic cancers.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Illustrate how cutting-edge data presented at the 2021 Annual Meeting of the American Society of Hematology (ASH) can apply to clinical practice, addressing best practices and guidelines;
2. State the emerging treatment strategies for patients with low- and high-risk myeloid malignancies;
3. Discuss the optimal patient selection, timing, and regimen for transplant;
4. Evaluate clinical trial data in the context of cellular CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
5. Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
6. Identify methods for integrating therapeutic advances such as CAR-T therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) into practice for myeloma patient care;
7. Describe the pathogenesis, diagnostic evaluation and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.

CONFERENCE LOCATION

IN-PERSON:

David Rubenstein Forum at the University of Chicago
1201 East 60th Street, Chicago, Illinois 60637

VIRTUAL:

Log in information will be sent 72 hours prior to conference.

AGENDA

PRE-CONFERENCE

- 9:30 am **REGISTRATION**
- 10:30 am **CONCURRENT SESSIONS**
Case Based Clinical Trial Considerations
Ajay Major, MD
Allied Health/Nursing Session
Mylove Mortel, MSPH, RN, OCN
- 11:30 am **BREAK | VISIT EXHIBITS | NETWORKING**
Relax Room (In-Person Only)
- 11:30 am **EXHIBITOR ROUNDTABLE** (In-Person Only)


MAIN CONFERENCE

- 12:00 pm **CONCURRENT SESSIONS**
Panel/Case Discussion
Moderator: Sonali Smith, MD
Panelists: Michael Drazer, MD | Adam DuVall, MD, MPH | Peter Riedell, MD
Fellows/Meet the Experts
- 12:30 pm **LUNCH | VISIT EXHIBITS | NETWORKING**
- 12:30 pm **PRODUCT THEATER**
- 1:30 pm **Strategies in Myeloid Malignancies**
Adam DuVall, MD, MPH
- 2:00 pm **Immunotherapies in Leukemia**
Hongtao Liu, MD
- 2:30 pm **BREAK | VISIT EXHIBITS | NETWORKING**
Relax Room (In-Person Only)
- 2:45 pm **Practice Changing and Promising New Treatments in Myeloma**
Benjamin Derman, MD
- 3:15 pm **Advances in Cellular Therapy & Transplant**
Mariam Nawas, MD
- 3:45 pm **BREAK | VISIT EXHIBITS | NETWORKING**
Relax Room (In-Person Only)
- 4:00 pm **Evolving Standards of Care in Lymphoma**
Justin Kline, MD
- 4:30 pm **Updates in Nonmalignant Hematology**
Kenneth Cohen, MD
- 5:00 pm **KEYNOTE: Myeloma**
Joseph Mikhael, MD, MEd, FRCPC, FACP
- 5:45 pm **ADJOURN**

FACULTY

COURSE DIRECTOR

Michael Bishop, MD
Professor of Medicine
Director of the Jonas Center
for Cellular Therapy
University of Chicago Medicine



KEYNOTE SPEAKER

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University

CONFERENCE FACULTY

Benjamin A. Derman, MD
Assistant Professor of Medicine
University of Chicago

Michael Drazer, MD
Assistant Professor of Medicine
University of Chicago

Adam Duvall, MD, MPH
Assistant Professor of Medicine
University of Chicago

Justin Kline, MD
Associate Professor of Medicine
University of Chicago

Hongtao Liu, MD, PhD
Associate Professor of Medicine
University of Chicago

Mariam Nawas, MD
Assistant Professor of Medicine
University of Chicago

Peter A. Riedell, MD
Assistant Professor of Medicine
University of Chicago



SCAN TO REGISTER!

HOW TO REGISTER: Please visit www.ChicagoPostASH.com